(Sacramento, CA) - Today, the California Assembly Health Committee overwhelmingly passed AB 2203 by Assemblymember Nazarian (D-Van Nuys), which would cap insulin copays at $50. Diabetes affects millions of Californians a year and the soaring prices of insulin have disrupted millions of lives. People with Type 1 diabetes and some with Type 2 diabetes must have insulin to live, but price increases for those whose coverage requires significant cost-sharing have made insulin unaffordable. This should not be the case. This bill implements much needed legislation that puts patients above profit. Ab 2203 is a concrete solution to the high-cost of insulin that is burdening people with diabetes across the state and an essential step to fulfilling our promise to all working families of California.
“I know that this uncertain time during the COVID-19 pandemic is difficult for us all, and many Californians are struggling to survive. My bill, AB 2203, aims to help Californians with diabetes by lowering the out-of-pocket costs for insulin so they can stick to their treatment plan outlined by their physician. When insulin is not taken appropriately, the risk of serious complications and death increases quickly. During the COVID-19 pandemic, it is even more critical to lower copays to ensure Californians with diabetes can afford their life-saving insulin prescriptions and stay on their insulin regimens,” said Assemblymember Nazarian.